Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NetraMark Holdings ( (TSE:AIAI) ) has shared an update.
NetraMark Holdings Inc. has entered into an agreement with AlgoTherapeutix SAS to enhance clinical trial design for ATX01, a treatment for chemotherapy-induced peripheral neuropathy. Utilizing NetraMark’s NetraAI platform, the collaboration aims to optimize trial design by analyzing patient data to identify responder personas and improve trial success through enriched patient populations. This partnership highlights AlgoTx’s commitment to leveraging advanced AI technologies to accelerate the development of transformative therapies for patients.
More about NetraMark Holdings
NetraMark Holdings Inc. is a leader in the development of Generative Artificial Intelligence and Machine Learning solutions aimed at the pharmaceutical industry. Their innovative technology utilizes a novel topology-based algorithm to analyze patient data, enabling precise disease segmentation and patient classification for drug sensitivity and treatment efficacy.
YTD Price Performance: 42.16%
Average Trading Volume: 56,635
Technical Sentiment Signal: Buy
Current Market Cap: C$109.5M
See more data about AIAI stock on TipRanks’ Stock Analysis page.